BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenomeDx to Present Validation and Utility Data on Decipher™ Test for Prostate Cancer at ASCO Genitourinary Cancers Symposium


2/8/2013 9:43:43 AM

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced that four posters highlighting the performance and clinical utility of its Decipher test will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). Decipher is a transformative genomic decision tool that provides accurate and actionable information to forecast patients that are at risk for lethal prostate cancer. Abstracts will be made available to the public on February 12 at 6:00 p.m. ET. The conference is taking place February 14-16 in Orlando, Florida.

The schedule for the Decipher poster presentations at ASCO GU follows:

Thursday, February 14, 11:45 a.m. to 1:15 p.m. and 5:05 p.m. to 6:35 p.m. Gatlin Ballroom B
General Poster Session A: Prostate Cancer

  • Abstract #36: Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with High Risk Pathological Features Post-prostatectomy
  • Abstract #52: Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with Biochemical Recurrence Post Radical Prostatectomy
  • Abstract #60: Combined Value of Genomic Biomarkers and CAPRA-S in Predicting Prostate Cancer Death in a High-Risk Surgical Cohort

Friday, February 15, 12:15 p.m. to 1:45 p.m. and 5:15 p.m. to 6:45 p.m. Gatlin Ballroom B
General Poster Session B: Prostate, Penile, Urethral and Testicular Cancer, and Urothelial Carcinoma

  • Abstract #196: Evaluation of a Genomic-based Prognostic Test for Metastasis in High-risk Post-prostatectomy Patients: Does it Impact Physician Decision Making?

About Decipher

Decipher is a transformative prognostic test that provides a direct measure of the true biological risk of lethal prostate cancer independent of PSA and other risk factors. Decipher measures the expression levels of multiple markers associated with aggressive prostate cancer and provides additional information about a patient's risk of disease progression after surgery (radical prostatectomy). When used in conjunction with conventional risk assessment tools, Decipher has the potential to more accurately stratify a patient's risk for developing recurrent or metastatic cancer following radical prostatectomy.

About GenomeDx Biosciences

GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher, is a transformative prognostic test that provides a direct measure of the true biological risk of lethal metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, Canada. More information is available at www.genomedx.com.

SOURCE GenomeDx



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES